Drug Research
Zydus partners with CHEMI of Italy to launch Enoxaparin Sodium Injection in the United States
Zydus Pharmaceuticals Inc, USA (a 100% subsidiary of Cadila Healthcare Limited (Zydus Cadila), a leading innovation-driven, global healthcare provider, has signed a license and supply agreement with CHEMI SpA (“CHEMI”) of Italy, a subsidiary of Italfarmaco Group, to launch...
Drug Research
SomaLogic and Twist Bioscience Corporation announce partnership to discover novel therapeutic targets and antibodies
CM Life Sciences II and SomaLogic, Inc., a leader in AI-data driven proteomics technology, and Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration...
Drug Research
Gritstone and CEPI Announce Agreement to Advance Second-Generation COVID-19 Vaccine Program Against SARS-CoV-2 Variants of Concern
Gritstone bio, Inc., a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, announced that the company entered into a funding agreement of up to $20.6 million with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance...
Drug Research
Exelixis and Invenra expand partnership to develop cancer antibodies
Exelixis and Invenra have extended their discovery and licensing partnership to include 20 more oncology targets for multi-specific antibodies, antibody-drug conjugates, and the development of other biologic candidates.
In May 2018, the companies collaborated to discover and develop mono-specific and...
Drug Research
Sinopharm signs with Bangladesh to jointly produce COVID-19 vaccines
Chinese pharmaceutical giant Sinopharm has signed an agreement with Bangladesh over the co-production of COVID-19 inactivated vaccines. Five million vaccines will be finished and dispensed monthly in the Bangladeshi capital Dhaka if everything goes to plan.
The chairman of Sinopharm,...
Drug Research
Seagen and RemeGen enter up to $2.6bn deal for cancer drug
Seagen and a Chinese company, RemeGen, have signed an exclusive global licencing agreement to develop and market a new HER2-targeted antibody-drug conjugate (ADC), disitamab vedotin.
Merging Seagen’s drug-linker technology with RemeGen’s new HER2 antibody, disitamab vedotin selectively carries the anti-cancer...
Drug Research
Heraeus completes multi-million Euro cancer therapy API capacity expansion
Heraeus Pharmaceutical Ingredients’ additional production line for Platinum-based highly potent active pharmaceutical ingredients (Pt hAPIs) is now fully operational at the company’s headquarters in Hanau, Germany.
Heraeus, a business line of Heraeus Precious Metals, is the leading global market supplier...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
